Viking Therapeutics (NASDAQ:VKTX – Get Free Report)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a research report issued on Thursday,Benzinga reports. They currently have a ...

CEO Brian Lian highlighted 2024 as an exceptionally ... as higher doses are explored in oral VK2735 trials. Viking Therapeutics showcased significant clinical progress across its pipeline in ...

Shares of Viking Therapeutics has fallen heavily in value in recent months, but at $3.5 billion, the company's market capitalization remains high for a business with no approved products to date.

But if it falls short of expectations, then more of a sell-off could ensue. Shares of Viking Therapeutics has fallen heavily in value in recent months, but at $3.5 billion, the company's market ...

I would now like to turn the conference over to Viking's Manager of Investor Relations, Stephanie Diaz. Please go ahead, Stephanie. Hello and thank you all for participating in today's call. Joining ...

The excitement surrounding Viking Therapeutics (NASDAQ: VKTX) stock has been dying down significantly lately. In six months, the stock has lost more than 40% of its value. Many investors may have ...

Hello and thank you all for participating in today's call. Joining me today is Brian Lian, Viking's President and CEO; and Greg Zante, Viking's CFO. Before we begin, I'd like to caution that ...